Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Angiogenesis (5)
- Macular (4)
- Degeneration (3)
- Device (3)
- Drugs (3)
-
- Inhibitors (3)
- Methods (3)
- Neovascularization (3)
- Ocular (3)
- Age-related (2)
- Age-related macular degeneration (2)
- Binding (2)
- Compositions (2)
- Controlled (2)
- Degernation (2)
- Deliver (2)
- Drug (2)
- Implantable (2)
- Inhibition (2)
- Inhibitor (2)
- Internal body (2)
- Internal portion (2)
- Method (2)
- Nucleoside (2)
- Ocular angiogenesis (2)
- RNA (2)
- Retinal damage (2)
- Reverse transcriptase inhibitor (2)
- Sustained release (2)
- Targets (2)
Articles 1 - 27 of 27
Full-Text Articles in Ophthalmology
Compositions And Methods For Treating Retinal Degradation, Jayakrishna Ambati, Benjamin Fowler
Compositions And Methods For Treating Retinal Degradation, Jayakrishna Ambati, Benjamin Fowler
Ophthalmology and Visual Science Faculty Patents
The present disclosure relates to compositions and methods for treating retinal damage and/or retinal degradation. More specifically, this disclosure relates to methods for treating degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a nucleoside or nucleotide reverse transcriptase inhibitor.
Methods Of Administering Igg1 Antibodies And Methods Of Suppressing Angiogenesis, Jayakrishna Ambati, Sandro De Falco
Methods Of Administering Igg1 Antibodies And Methods Of Suppressing Angiogenesis, Jayakrishna Ambati, Sandro De Falco
Ophthalmology and Visual Science Faculty Patents
A method of suppressing angiogenesis involves administering to a subject an isolated Fc fragment of an IgG1 antibody, or an IgG1 antibody.
Ccr3 Inhibition For Ocular Angiogenesis And Macular Degeneration, Jayakrishna Ambati
Ccr3 Inhibition For Ocular Angiogenesis And Macular Degeneration, Jayakrishna Ambati
Ophthalmology and Visual Science Faculty Patents
Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis.
Protection Of Cells From Degeneration And Treatment Of Geographic Atrophy, Jayakrishna Ambati
Protection Of Cells From Degeneration And Treatment Of Geographic Atrophy, Jayakrishna Ambati
Ophthalmology and Visual Science Faculty Patents
Therapeutic uses P2X7 inhibition and inhibition of IRAK1 and/or IRAK4, methods protecting a cell, and screening methods for identifying inhibitors are described herein.
Methods Of Inhibiting Alu Rna And Therapeutic Uses Thereof, Jayakrishna Ambati
Methods Of Inhibiting Alu Rna And Therapeutic Uses Thereof, Jayakrishna Ambati
Ophthalmology and Visual Science Faculty Patents
The presently-disclosed subject matter includes methods of identifying an Alu RNA inhibitor, and methods and compositions for inhibiting Alu RNA. Methods and compositions can be used for the treatment of geographic atrophy and other conditions of interest.
Protection Of Cells From Alu-Rna-Induced Degeneration And Inhibitors For Protecting Cells, Jayakrishna Ambati, Valeria Tarallo
Protection Of Cells From Alu-Rna-Induced Degeneration And Inhibitors For Protecting Cells, Jayakrishna Ambati, Valeria Tarallo
Ophthalmology and Visual Science Faculty Patents
A method of protecting a cell includes inhibiting an inflammasome, MyD88, IL-18, VDAC1, VDAC2, caspase-8, and/or NFκB of the cell. Administering an inhibitor of MyD88, IL-18, VDAC1, VDAC2, caspase-8, and/or NFκB can protect the cell from Alu-RNA-induced degeneration. Protecting a cell, such as an retinal pigment epithelium (RPE), can be therapeutically useful in the context of age-related macular degeneration and geographic atrophy.
Compositions And Methods For Treating Retinal Degradation, Jayakrishna Ambati, Benjamin J. Fowler
Compositions And Methods For Treating Retinal Degradation, Jayakrishna Ambati, Benjamin J. Fowler
Ophthalmology and Visual Science Faculty Patents
The present disclosure relates to compositions and methods for treating retinal damage and/or retinal degradation. More specifically, this disclosure relates to methods for treating degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a nucleoside or nucleotide reverse transcriptase inhibitor.
Modulation Of Angiogenesis, Balamurali Krishna Ambati, Jayakrishna Ambati, Nirbhai Singh
Modulation Of Angiogenesis, Balamurali Krishna Ambati, Jayakrishna Ambati, Nirbhai Singh
Ophthalmology and Visual Science Faculty Patents
This invention relates to compounds, composJtwns, and methods for the treatment of traits, diseases and conditions that respond to the modulation of angiogenic growth factor bioavailability or biological activity.
Toll Like Receptor (Tlr) Stimulation For Ocular Angiogenesis And Macular Degeneration, Jayakrishna Ambati
Toll Like Receptor (Tlr) Stimulation For Ocular Angiogenesis And Macular Degeneration, Jayakrishna Ambati
Ophthalmology and Visual Science Faculty Patents
Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of stimulators of the TLR3 and TLR7 receptors, Trif or of IL-10 and IL-12 inhibits ocular angiogenesis. Furthermore, all siRNAs (both targeted and non-targeted) can inhibit ocular angiogenesis.
Svegfr-2 And Its Role In Lymphangiogenesis Modulation, Jayakrishna Ambati, Romulo J. Albuquerque
Svegfr-2 And Its Role In Lymphangiogenesis Modulation, Jayakrishna Ambati, Romulo J. Albuquerque
Ophthalmology and Visual Science Faculty Patents
Disclosed herein are nucleic acid molecules comprising a nucleotide sequence of sVEGF-2, proteins encoded by those sequences and antibodies that bind to the protein. Also disclosed are methods for inhibiting or enhancing expression or activity of sVEGFR-2 and methods for inhibiting graft rejection, particularly cornea graph rejection. Also described are methods for inhibiting lymphangiogenesis and lymphatic endothelial cell proliferation by administering an effective amount of sVEGFR-2 and methods for treating lymphedema by inhibiting the activity of sVEGFR-2.
Method Of Using Ccr3 Binding Agents To Detect Choroidal Neovascularization, Jayakrishna Ambati, Mark E. Kleinman
Method Of Using Ccr3 Binding Agents To Detect Choroidal Neovascularization, Jayakrishna Ambati, Mark E. Kleinman
Ophthalmology and Visual Science Faculty Patents
The results presented herein demonstrate the specific expression of CCR3 in CNV endothelial cells in humans with AMD, and despite the expression of its ligands, eotaxin-1, -2, and -3, neither eosinophils nor mast cells are present in human CNV. The genetic or pharmacological targeting of CCR3 or eotaxins as disclosed herein inhibited injury-induced CNV in mice. CNV suppression by CCR3 blockade was due to direct inhibition of endothelial cell proliferation, and was uncoupled from inflammation as it occurred in mice lacking eosinophils or mast cells and was independent of macrophage and neutrophil recruitment. CCR3 blockade was more effective at reducing …
Withanolides, Probes And Binding Targets And Methods Of Use Thereof, Royce Mohan, Paola Bargagna-Mohan, Kyung Bo Kim
Withanolides, Probes And Binding Targets And Methods Of Use Thereof, Royce Mohan, Paola Bargagna-Mohan, Kyung Bo Kim
Ophthalmology and Visual Science Faculty Patents
Novel withanolide chemical genetic probes identify the in vivo binding target of withaferin A, which is the intermediate filament type III protein vimentin. In addition, a withanolide-based small molecule screening method screens drug candidates that target intermediate filament type III proteins. The method includes introducing a tagged linker covalently bonded to the withanolide molecule to form a withanolide probe. Better or alternative small molecule compounds as potential drug candidates can be generated based on their likely affinity for the determined binding site in vimentin. The affinity labeled withanolide can also be used to find intermediate filament-associated proteins using chemical proteomics …
Ccr3 Inhibition For Ocular Angiogenesis And Macular Degeneration, Jayakrishna Ambati
Ccr3 Inhibition For Ocular Angiogenesis And Macular Degeneration, Jayakrishna Ambati
Ophthalmology and Visual Science Faculty Patents
Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis.
Ultra-Small Rnas As Toll-Like Receptor-3 Antagonists, Jayakrishna Ambati
Ultra-Small Rnas As Toll-Like Receptor-3 Antagonists, Jayakrishna Ambati
Ophthalmology and Visual Science Faculty Patents
Provided are methods and compositions for the treatment or prevention of macular degeneration or other diseases or disorders associated with activation of TLR3. Administration of double stranded RNAs having a length of 22 nucleotides or less treats or prevents macular degeneration or other diseases or disorders associated with activation of TLR3 due to the ability of the RNAs to bind to but not activate TLR3. Furthermore, all double stranded RNAs (both targeted and non-targeted) of 22 nucleotides or less in length can bind to but not activate TLR3 and thereby treat or prevent such conditions. Also provided of a method …
Withanolide Compounds As Inhibitors Of Fibrosis And Identification Of Molecular Targets For Anti-Fibrotic Drug Development, Royce Mohan, Paola Bargagna-Mohan
Withanolide Compounds As Inhibitors Of Fibrosis And Identification Of Molecular Targets For Anti-Fibrotic Drug Development, Royce Mohan, Paola Bargagna-Mohan
Ophthalmology and Visual Science Faculty Patents
Provided are methods for screening for drugs effective for treating fibrotic conditions. One screening method comprises exposing a cell to a test compound, monitoring the effect of the test compound on the amount or form of a cell molecule, comparing the amount or form of the cell molecule with the result obtained by treatment of the cell with an anti-fibrotic -effective amount of a withanolide compound, and selecting a drug effective for treating a fibrotic disease based on the ability of the test compound to provide the effect obtained by the withanolide compound on the cell molecule. Also provided is …
Ccr3 Inhibition For Ocular Angiogenesis And Macular Degeneration, Jayakrishna Ambati
Ccr3 Inhibition For Ocular Angiogenesis And Macular Degeneration, Jayakrishna Ambati
Ophthalmology and Visual Science Faculty Patents
Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis.
Methods And Animal Model For Analyzing Age-Related Macular Degeneration, Jayakrishna Ambati
Methods And Animal Model For Analyzing Age-Related Macular Degeneration, Jayakrishna Ambati
Ophthalmology and Visual Science Faculty Patents
Methods for testing candidate drugs for treatment of age-related macular degeneration are provided. Ccl2-deficient, and Ccr2-deficient mice are used to determine the effect of candidate drugs and treatments on development of age-related macular degeneration. Also provided is a Ccl2-deficient, Ccr2-deficient dual knockout mouse, which is a useful animal model for age-related macular degeneration.
Compositions And Methods For Inhibiting Drusen Complement Components C3a And C5a For The Treatment Of Age-Related Macular Degeneration, Jayakrishna Ambati
Compositions And Methods For Inhibiting Drusen Complement Components C3a And C5a For The Treatment Of Age-Related Macular Degeneration, Jayakrishna Ambati
Ophthalmology and Visual Science Faculty Patents
Activated C3 (C3a) and its receptor (C3aR) and activated C5 (C5a) and its receptor (C5aR) have been shown to induce vascular endothelial growth factor (VEGF) expression in vitro and in vivo. Compositions and methods for inhibiting C3a, C3aR, C5a and C5aR for the treatment and/or prevention of neovascular disease are provided. Also provided are Novel therapeutic targets and diagnostic markers for choroidal neovascularization.
Methods And Animal Model For Analyzing Age-Related Macular Degeneration, Jayakrishna Ambati
Methods And Animal Model For Analyzing Age-Related Macular Degeneration, Jayakrishna Ambati
Ophthalmology and Visual Science Faculty Patents
Methods for testing candidate drugs for treatment of age-related macular degeneration are provided. Ccl2-deficient, and Ccr2-deficient mice are used to determine the effect of candidate drugs and treatments on development of age-related macular degeneration. Also provided is a Ccl2-deficient, Ccr2-deficient dual knockout mouse, which is a useful animal model for age-related macular degeneration.
Vegf-A As An Inhibitor Of Angiogenesis And Methods Of Using Same, Jayakrishna Ambati
Vegf-A As An Inhibitor Of Angiogenesis And Methods Of Using Same, Jayakrishna Ambati
Ophthalmology and Visual Science Faculty Patents
The invention relates to methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization associated with neovascular disease. Administration of vascular endothelial growth factor (VEGF)-A into the eye when macrophage infiltration is reduced inhibits ocular angiogenesis.
Method Of Inhibiting Alu Rna And Therapeutic Uses Thereof, Jayakrishna Ambati
Method Of Inhibiting Alu Rna And Therapeutic Uses Thereof, Jayakrishna Ambati
Ophthalmology and Visual Science Faculty Patents
The presently-disclosed subject matter includes methods of identifying an Alu RNA inhibitor, and methods and compo sitions for inhibiting Alu RNA. Methods and compositions can be used for the treatment of geographic atrophy and other conditions of interest.
Means To Achieve Sustained Release Of Synergistic Drugs By Conjugation, Paul Ashton, Peter A. Crooks, Tadeusz Cynkowski, Grazyna Cynkowska, Hone Guo
Means To Achieve Sustained Release Of Synergistic Drugs By Conjugation, Paul Ashton, Peter A. Crooks, Tadeusz Cynkowski, Grazyna Cynkowska, Hone Guo
Ophthalmology and Visual Science Faculty Patents
A codrug composition of at least two drug compounds covalently linked to one another via a labile bond to form a single codrug composition, or ionically linked to one another to form a single workings composition, and methods of use of the codrug for the treatment of various medical conditions. The codrug may be administered by itself or in the form of a bioerodible or nonbioerodible substance.
Implantable Controlled Release Device To Deliver Drugs Directly To An Internal Portion Of The Body, Paul Ashton, Paul A. Pearson
Implantable Controlled Release Device To Deliver Drugs Directly To An Internal Portion Of The Body, Paul Ashton, Paul A. Pearson
Ophthalmology and Visual Science Faculty Patents
A simple and implantable sustained release drug delivery device with an inner core containing an effective amount of a low solubility agent covered by a non-bioerodible polymer coating layer that is permeable to the low solubility agent is disclosed. A method for treating a mammal to obtain a desired local or systemic physiological or pharmacological effect by surgically implanting such a sustained release drug delivery device into a mammal in need of treatment is also disclosed.
Implantable Controlled Release Device To Deliver Drugs Directly To An Internal Portion Of The Body, Paul Ashton, Paul A. Pearson
Implantable Controlled Release Device To Deliver Drugs Directly To An Internal Portion Of The Body, Paul Ashton, Paul A. Pearson
Ophthalmology and Visual Science Faculty Patents
A simple and implantable sustained release drug delivery device with an inner core containing an effective amount of a low solubility agent covered by a non-bioerodible polymer coating layer that is permeable to the low solubility agent is disclosed. A method for treating a mammal to obtain a desired local or systemic physiological or pharmacological effect by surgically implanting such a sustained release drug delivery device into a mammal in need of treatment is also disclosed.
Permeable, Non-Irritating Prodrugs Of Nonsteroidal And Steroidal Agents, Paul Ashton, Thomas J. Smith, Peter G. Glavinos, John D. Conklin, Peter A. Crooks, Robert M. Riggs, Tadeusz Cynkowski, Grazyna Cynkowska
Permeable, Non-Irritating Prodrugs Of Nonsteroidal And Steroidal Agents, Paul Ashton, Thomas J. Smith, Peter G. Glavinos, John D. Conklin, Peter A. Crooks, Robert M. Riggs, Tadeusz Cynkowski, Grazyna Cynkowska
Ophthalmology and Visual Science Faculty Patents
Prodrugs containing an active drug molecule linked to a polyethylene glycol group, and a method of use thereof are described. Exemplary soluble ester prodrugs contain naproxen, triamcinolone acetonide, gancyclovir, taxol, cyclosporin, dideoxyinosine, trihydroxy steroids, and flurbiprofen molecules linked to polyethylene glycol (PEG) groups. Pharmaceutical compositions containing these prodrugs, and a method of using these esters for treating disease states or symptoms are also described.
Apparatus And Method For Restoring Eyelid Function, Robert S. Baker, Brian J. Willoughby, Robert R. Marshall
Apparatus And Method For Restoring Eyelid Function, Robert S. Baker, Brian J. Willoughby, Robert R. Marshall
Ophthalmology and Visual Science Faculty Patents
An apparatus is provided to restore eyelid function in a patient unable to voluntarily raise an eyelid. The apparatus includes a spiral torsion spring and pulley arrangement mounted in a housing that is implanted in the superior portion of the orbit of the eye. A wire connects the pulley to the eyelid. A spiral torsion spring provides the necessary spring force in tension to overcome the weight of the eyelid and draw the eyelid open. The natural muscles of eye closure are, however, sufficiently strong to overcome the spring tension thereby paying out wire from the pulley and closing the …
Sustained Release Drug Delivery Devices, Thomas J. Smith, Paul Ashton, Paul A. Pearson
Sustained Release Drug Delivery Devices, Thomas J. Smith, Paul Ashton, Paul A. Pearson
Ophthalmology and Visual Science Faculty Patents
A method and device for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect is provided. The method includes administering a sustained release drug delivery system to a mammalian organism in need of such treatment at an area wherein release of an effective agent is desired and allowing the effective agent to pass through the device in a controlled manner. The device includes an inner core or reservoir comprising the effective agent; a first coating layer, which is essentially impermeable to the passage of the effective agent; and a second coating layer, which is …